199 related articles for article (PubMed ID: 25296094)
1. The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease.
Yadav P; Leung N; Sanders PW; Cockwell P
Kidney Int; 2015 Apr; 87(4):692-7. PubMed ID: 25296094
[TBL] [Abstract][Full Text] [Related]
2. [5th International Symposium on clinical applications of serum free light chain analysis].
Decaux O
Rev Med Interne; 2009 Jan; 30(1):96-100. PubMed ID: 19054596
[No Abstract] [Full Text] [Related]
3. Strengths and weaknesses of methods for identifying monoclonal free light chains of Ig: examples from two cases with renal disease.
Levinson SS
Clin Chem Lab Med; 2016 Jun; 54(6):1039-43. PubMed ID: 26368046
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Impact of Renal Failure on Correlation and Concordance Between 2 Free Light Chain Assays.
Moreau C; Autier B; Cavey T; Rouger E; Norwood J; Bendavid C; Escoffre M; Sébillot M; Decaux O
Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):693-704. PubMed ID: 27618362
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.
Ludwig H; Milosavljevic D; Zojer N; Faint JM; Bradwell AR; Hübl W; Harding SJ
Leukemia; 2013 Jan; 27(1):213-9. PubMed ID: 22955329
[TBL] [Abstract][Full Text] [Related]
6. Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies?
Beetham R; Wassell J; Wallage MJ; Whiteway AJ; James JA
Ann Clin Biochem; 2007 Nov; 44(Pt 6):516-22. PubMed ID: 17961305
[TBL] [Abstract][Full Text] [Related]
7. Non-crystalline light chain proximal tubulopathy, a morphologically protean entity.
Kousios A; Blakey S; Moran L; Atta M; Charif R; Duncan N; Smith A; Tam FWK; Levy JB; Chaidos A; Roufosse C
Nephrol Dial Transplant; 2023 Oct; 38(11):2576-2588. PubMed ID: 37120733
[TBL] [Abstract][Full Text] [Related]
8. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays.
Katzmann JA; Dispenzieri A; Kyle RA; Snyder MR; Plevak MF; Larson DR; Abraham RS; Lust JA; Melton LJ; Rajkumar SV
Mayo Clin Proc; 2006 Dec; 81(12):1575-8. PubMed ID: 17165636
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin light-chain toxicity in a mouse model of monoclonal immunoglobulin light-chain deposition disease.
Bender S; Ayala MV; Bonaud A; Javaugue V; Carrion C; Oblet C; Rinsant A; Kaaki S; Oruc Z; Boyer F; Paquet A; Pons N; Hervé B; Ashi MO; Jaccard A; Delpy L; Touchard G; Cogné M; Bridoux F; Sirac C
Blood; 2020 Oct; 136(14):1645-1656. PubMed ID: 32559766
[TBL] [Abstract][Full Text] [Related]
10. A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine.
Leung N; Nasr SH
Clin J Am Soc Nephrol; 2016 Jun; 11(6):1073-1082. PubMed ID: 26992418
[TBL] [Abstract][Full Text] [Related]
11. [Comparative analysis of immunoglobulin free light chains quantification by Freelite™ (The Binding Site) and N Latex FLC (Siemens) methods].
Schneider N; Wynckel A; Kolb B; Sablon E; Gillery P; Maquart FX
Ann Biol Clin (Paris); 2013; 71(1):13-9. PubMed ID: 23396425
[TBL] [Abstract][Full Text] [Related]
12. Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.
Milani P; Palladini G; Merlini G
Scand J Clin Lab Invest Suppl; 2016; 245():S113-8. PubMed ID: 27467897
[TBL] [Abstract][Full Text] [Related]
13. The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.
Greil C; Ihorst G; Gaiser F; Salzer U; Bisse E; Kastritis E; Ludwig H; Wäsch R; Engelhardt M
Eur J Haematol; 2017 Nov; 99(5):449-458. PubMed ID: 28886228
[TBL] [Abstract][Full Text] [Related]
14. Rapid Deterioration of the Renal Function Caused by the Coexistence of Intratubular Amyloidosis and Myeloma Cast Nephropathy.
Kato H; Fujigaki Y; Asakawa S; Yamaguchi Y; Uozaki H; Komatsuda A; Nagata M; Uchida S
Intern Med; 2015; 54(23):3023-8. PubMed ID: 26631886
[TBL] [Abstract][Full Text] [Related]
15. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
[TBL] [Abstract][Full Text] [Related]
16. Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma.
Yadav P; Cockwell P; Cook M; Pinney J; Giles H; Aung YS; Cairns D; Owen RG; Davies FE; Jackson GH; Child JA; Morgan GJ; Drayson MT
BMC Nephrol; 2018 Jul; 19(1):178. PubMed ID: 30012107
[TBL] [Abstract][Full Text] [Related]
17. Novel extended reference range for serum kappa/lambda free light chain ratio in diagnosing monoclonal gammopathies in renal insufficient patients.
Diamantidis MD; Ioannidou-Papagiannaki E; Ntaios G
Clin Biochem; 2009 Jul; 42(10-11):1202-3. PubMed ID: 19375413
[No Abstract] [Full Text] [Related]
18. How lab staff and the estimation of free light chains can combine to aid the diagnosis of light chain disease.
Sinclair D; Wainwright L
Clin Lab; 2007; 53(5-6):267-71. PubMed ID: 17605400
[TBL] [Abstract][Full Text] [Related]
19. Practical considerations for the measurement of free light chains in serum.
Tate JR; Gill D; Cobcroft R; Hickman PE
Clin Chem; 2003 Aug; 49(8):1252-7. PubMed ID: 12881439
[TBL] [Abstract][Full Text] [Related]
20. Renal manifestations of plasma cell dyscrasias: an appraisal from the patients' bedside to the research laboratory.
Herrera GA
Ann Diagn Pathol; 2000 Jun; 4(3):174-200. PubMed ID: 10919389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
